10-KPeriod: FY2020

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 2020

Filed February 10, 2021For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb's (BMY) 2020 10-K filing reveals a year marked by significant integration following the Celgene acquisition, which impacted revenue streams and operational focus. The company is navigating the post-acquisition landscape, emphasizing growth from key in-line products and its pipeline, while also addressing the ongoing pressures of competition and evolving regulatory environments in the pharmaceutical industry. Investors should note the strategic importance of the Celgene integration, which is expected to drive long-term value through enhanced product portfolios in areas like oncology and immunology. The company's performance is closely tied to the success of its major therapeutic areas and its ability to innovate and bring new treatments to market amidst patent expirations and the rise of biosimilars. Diligence in monitoring R&D progress, commercial execution, and capital allocation strategies will be crucial for understanding BMY's future trajectory.

Financial Highlights

57 data points
Beta

Revenue

$42.52B

72.3% Gross Margin

Net Income

-$9.02B

-21.2% Net Margin

EPS (Diluted)

$-3.99

Total Assets

$118.48B

Cash & Equivalents

$14.55B

Free Cash Flow

$13.30B

Financial Statements
Beta
Revenue$42.52B
Cost of Revenue$11.77B
Gross Profit$30.75B
R&D Expenses$10.05B
SG&A Expenses$7.66B
Operating Expenses$49.39B
Interest Expense$1.42B
Net Income-$9.02B
EPS (Basic)$-3.99
EPS (Diluted)$-3.99
Shares Outstanding (Basic)2.26B
Shares Outstanding (Diluted)2.26B

Key Highlights

  • 1The 2020 fiscal year was heavily influenced by the integration of the Celgene acquisition, impacting revenue and operational focus.
  • 2Key growth drivers include established products within BMY's portfolio, particularly in oncology and immunology.
  • 3Significant investment in Research and Development (R&D) continues, with a focus on advancing a robust pipeline of innovative therapies.
  • 4The company is actively managing its product portfolio, balancing the lifecycle of existing drugs with the introduction of new treatments.
  • 5BMY faces ongoing competition from other pharmaceutical companies and the increasing prevalence of generic and biosimilar drugs.
  • 6The financial statements detail substantial assets and liabilities, reflecting the scale of operations and the impact of recent M&A activity.

Frequently Asked Questions

The acquisition of Celgene significantly reshaped BMY's financial profile, contributing to changes in revenue, cost of goods sold, and operating expenses due to the integration of Celgene's assets and operations. Investors can find detailed segment reporting and the impact on the consolidated statements of earnings in the Management's Discussion and Analysis section.

BMY continues to invest heavily in R&D to develop new therapies and expand indications for existing drugs. The filing highlights ongoing clinical trials and strategic R&D initiatives aimed at addressing unmet medical needs in areas like oncology, immunology, and cardiovascular diseases.

Key risks include intense competition within the pharmaceutical industry, pricing pressures from governments and payers, patent expirations leading to generic or biosimilar competition, and the inherent uncertainties and costs associated with drug development and regulatory approvals. The 'Risk Factors' section provides an extensive overview of these challenges.

The company discusses its strategies for navigating complex pricing environments and ensuring market access for its products. This involves engaging with healthcare providers, payers, and policymakers to demonstrate the value of its therapies, while also adapting to evolving healthcare reforms and reimbursement policies globally.